Cantor Fitzgerald Issues Negative Estimate for DNLI Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities researchers at Cantor Fitzgerald dropped their FY2025 EPS estimates for shares of Denali Therapeutics in a note issued to investors on Thursday, April 10th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings per share of ($3.04) for the year, down from their prior forecast of ($3.00). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share.

Several other equities analysts also recently commented on DNLI. Oppenheimer dropped their price target on shares of Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. B. Riley reaffirmed a “buy” rating and issued a $35.00 target price (down previously from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th. Robert W. Baird started coverage on Denali Therapeutics in a report on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 price target for the company. Morgan Stanley began coverage on Denali Therapeutics in a research note on Friday, March 7th. They set an “overweight” rating and a $33.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They set a “buy” rating and a $31.00 target price on the stock. One research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $37.57.

Denali Therapeutics Trading Down 0.8 %

Shares of DNLI opened at $13.17 on Monday. The firm has a market cap of $1.91 billion, a P/E ratio of -4.77 and a beta of 1.58. The company’s 50-day moving average price is $16.14 and its 200 day moving average price is $21.60. Denali Therapeutics has a 12-month low of $10.57 and a 12-month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.08.

Hedge Funds Weigh In On Denali Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC boosted its position in shares of Denali Therapeutics by 589.9% during the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock worth $36,000 after purchasing an additional 1,516 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Denali Therapeutics in the 4th quarter valued at approximately $62,000. Point72 Hong Kong Ltd bought a new stake in Denali Therapeutics during the 4th quarter worth approximately $65,000. PNC Financial Services Group Inc. raised its holdings in Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock worth $77,000 after buying an additional 885 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in shares of Denali Therapeutics by 253.8% in the first quarter. GAMMA Investing LLC now owns 7,953 shares of the company’s stock valued at $108,000 after buying an additional 5,705 shares during the period. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.